MarketBeat
07 Nov 2026, 09:21 UTC · 1h ago
Edwards Lifesciences Q3 Earnings Call Highlights
Impact · against what's priced in
Edwards Lifesciences provides a positive catalyst through raised FY2026 guidance and strong growth in mitral/tricuspid therapies. For Boston Scientific, the news confirms that its exit from non-U.S. TAVR markets has been fully absorbed by competitors, reinforcing the current pessimistic valuation of its international growth prospects.
- BSX−0.10
Already priced in
- The price assumes
Sustaining the strong 23% international growth seen in Q2
The news that Edwards has fully annualized the benefits of Boston Scientific's exit from European and other non-U.S. markets confirms the market's refusal to pay for a recovery in BSX's international TAVR footprint.
What BSX's price assumes · Sep 10
